Single-Patient trial tests heart drug for rare genetic syndrome
NCT ID NCT06534671
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a single intravenous dose of diltiazem, a calcium channel blocker, can shorten the QT interval in adults with Jervell and Lange-Nielsen syndrome, a rare genetic heart condition that increases the risk of dangerous heart rhythms. Only one person participated, and the researchers measured heart activity for up to 35 minutes after the drug was given. The goal was to see if diltiazem could quickly affect the heart's electrical activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- diltiazem (a calcium channel blocker given intravenously)
- What this could lead to
- If it works, this could point toward a way to temporarily shorten the QT interval and reduce the risk of dangerous heart rhythms in people with Jervell and Lange-Nielsen syndrome.
- What could go wrong
- This was a very small study with only one participant, so results may not apply to others. It only looked at immediate effects of a single dose, not long-term safety or benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JERVELL AND LANGE NIELSEN SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States